Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
247
self-reported band not used
Founded
1977
49 years
Legal entities
None matched
Office countries
1
1 address
Funding rounds
1
Corporate round · Jul 2020
Company type
Public Company
self-reported
Description
Established in 1977 in Dong Thap Province, Vietnam, Imexpharm is committed to delivering high-quality healthcare solutions through EU-GMP-standard products recognized for their safety, efficacy, and quality.
With nearly five decades of continuous growth, Imexpharm has established a solid foundation in research and development, cutting-edge technology, modern infrastructure, and sustainable practices, all driven by its vision “Trusted quality, European standard”. Today, Imexpharm is the No.1 producer of antibiotics in Vietnam and operates the most EU-GMP-certified production lines in the country, with three EU-GMP factory clusters and 12 EU-GMP certified lines. The company has also obtained 28 European MAUs for 11 products, affirming its global competitiveness.
In 2024, Imexpharm successfully completed its bonus share issuance, making it the largest listed pharmaceutical company in Vietnam by charter capital.
Imexpharm is a trusted contract manufacturing partner for global pharmaceutical leaders such as Sandoz, Sanofi-Aventis, Agimexpharm, Genuone Sciences Inc., and SK. The company is actively expanding into high-value, high-tech segments and advanced dosage forms, including injectables and dispersible tablets, to enhance healthcare accessibility in Vietnam and accelerate export growth across new markets.
Guided by the philosophy ‘1,000 years later, the lotus still blooms,’ Imexpharm, under strong leadership and with a team of over 1,400 dedicated professionals, remains steadfast in its pursuit of sustainable growth and long-term profitability, actively contributing to Vietnam’s vision of becoming a regional hub for high-value pharmaceutical manufacturing by 2030.
Specialties
All 1 specialty
- EU-GMP and Pharmaceutical
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|
All codes: VN
Addresses
- VN04 Đường 30 tháng4; Cao Lanh, Dong Thap
Grid intelligence Members
Funding
Rounds1
Round typeCorporate round · venture round
Amount (USD)not recorded
Stage ranknot recorded
Investors named1
Since last round5 yr 6 mo
Funding
Show as table · 1 funding round
| Rounds | 1 |
|---|---|
| Axis | 1977 to 2026 |
| Corporate round · 3 Jul 2020 | not disclosed |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
FAQ
How many people work at Imexpharm Corporation?
247 counted staff profiles at January 2026. The brand's self-reported band sits above that count and is not published as a headcount.
Where does Imexpharm Corporation have offices?
One address on record, Vietnam only.
Has Imexpharm Corporation raised funding?
One round. Latest 3 July 2020: corporate round, investor SK Group, no amount recorded.
What does Imexpharm Corporation list as its specialties?
One tag on the brand's own list, among them EU-GMP and Pharmaceutical.
Which companies are listed alongside Imexpharm Corporation?
95 profiles list Imexpharm Corporation as a peer — 99th percentile in Pharmaceutical Manufacturing. It lists ten peers of its own. Boston Pharma Vietnam and SEN Pharma list it back.